Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Rhegmatogenous Retinal Detachment: early-phase trial registry

3 of 4 indexed Rhegmatogenous Retinal Detachment trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Rhegmatogenous Retinal Detachment: 4 US clinical trials tracked, 3 recruiting.

Rhegmatogenous Retinal Detachment is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts Eye and Ear Infirmary, running 2 of these trials.

Enrollment posture brief

Registry condition rhegmatogenous-retinal-detachment

OPEN 3 | RECR 75% | LATE 1 | EARLY 3 | RANK #4115 | SPON 2

Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)

Ablation80%ACL Reconstruction80%Rhegmatogenous Retinal D (th…75%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Rhegmatogenous Retinal Detachment

Rhegmatogenous Retinal Detachment lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Rhegmatogenous Retinal Detachment on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Rhegmatogenous Retinal Detachment is recruiting above its size-band peers.

    3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 22Phase 41

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 4 1

Named interventions

Most-linked intervention names on Rhegmatogenous Retinal Detachment records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud Drug
1 trials
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] Drug
1 trials
Netarsudil Ophthalmic Drug
1 trials
Prednisolone 1% Drug
1 trials
Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin Drug
1 trials
Triamcinolone Acetonide 40mg/mL Drug
1 trials
Pars plana vitrectomy Procedure
1 trials
Sham Injection Drug
1 trials

US sites by state

Facility locations filed on Rhegmatogenous Retinal Detachment trials. A trial with sites in several states counts in each.

Massachusetts 2 trials
Pennsylvania 1 trials
Ohio 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Rhegmatogenous Retinal Detachment page

4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rhegmatogenous Retinal Detachment condition card totals 4 registered trials; most-linked intervention Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.